On April 21, 2016, Judge Eldon E. Fallon, the federal judge supervising and overseeing the centralized litigation against Janssen, Johnson & Johnson and Bayer over Xarelto, issued an order scheduling the depositions of plaintiffs and defense witnesses. The court is overseeing the discovery necessary to develop several “bellwether” trials in order to evaluate the strength and weaknesses of the cases brought against the pharmaceutical giants and to determine the values of certain harms and injuries. [Read more…]
Xarelto Release in 2011 Leads to Thousands of Serious Injuries by 2014, Consolidated Lawsuits Through 2016-2017
Xarelto Multidistrict Litigation – Case Update
The Xarelto multidistrict bellwether litigation is moving forward in the U.S. District Court in the Eastern District of Louisiana. The Court asked the parties in late December 2015 to select pool cases, which selection was completed January 11, 2016. The Court also requested that the chosen cases reflect multiple Xarelto injury categories, including gastrointestinal bleed and gi bleeding, brain bleeding events, hemorrhages, and hemorrhagic strokes. The Court is expected to select additional cases for inclusion originating in multiple states. The first trials are set for early February 2017 in Louisiana, with subsequent trials to occur in Mississippi and Texas in April and May 2017.
Drug’s Release in 2011 Leads to Thousands of Serious Injuries by 2014, Consolidated Lawsuits Through 2015
Xarelto was released in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use was then expanded to include patients with irregular heartbeats or facing likely lung and leg blood clots. It was also used to prevent clots in some people with atrial fibrillation. The drug is taken as a pill with the chemical name rivaroxaban. The new Xarelto patient information injury and lawsuit timeline shown below tracks Xarelto from its release to thousands of patient injury reports less than two years later, to thousands of Xarelto death and uncontrolled bleeding injury lawsuits slated for bellwether treatment in 2016 and 2017. [Read more…]
Patients charge that Xarelto is a dangerous and defective drug because in certain patients it triggers uncontrolled bleeding and other life-threatening complications. Xarelto was approved in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use has been expanded, including to patients with irregular heartbeats or facing a strong likelihood of blood clots in the legs or lungs.
Patients Allege Xarelto Linked to Serious Bleeding Risk
Wendy R. Fleishman of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced today that nearly two dozen lawsuits filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Corp. over the blood thinner Xarelto have been consolidated in Louisiana federal court. The U.S. Judiciary Panel on Multidistrict Litigation found that the cases have enough common complaints to warrant centralization. Xarelto has been linked to serious side effects including gastrointestinal bleeding, brain bleeding, other internal bleeds, and death. [Read more…]